Spotlight on dry aging beef: effects of loin type, aging methods, and aging time

Dry aging is an old-time process used to produce a high quality beef product marketed to high-end customers. Its most unique quality is the distinctive dry-aged flavor. Dry aging has been accomplished through many protocols over the years, but an optimum protocol has not been adopted. Practitioners of this art are very interested in providing a consistent, quality, safe product. Traditionally, dry aging is done without packaging, which places more emphasis on plant quality control practices to achieve a consistent product. This limits the number of processors that have the ability to produce dry-aged product. Packaging bags with a very high water vapor transmission rate that may simulate traditional dry aging are now available. If the quality from dry aging in these bags is equal to that obtained with the traditional unpackaged method, other processors might consider dry aging because this bag allows for less stringent facility needs and potentially greater yields. Overall, an in-thebag dry-aging system would require fewer controls and still result in decreased weight losses, which would provide a significant yield advantage. Objectives of this research were to determine the combined effects of two different dryaging methods (unpackaged and in the bag), two loin-cut styles (bone-in shell loins and boneless strip loins), and two aging times (21 and 28 days) on flavor, juiciness, tenderness, palatability, development of the unique dry-aged flavor, moisture vapor loss, and microbial growth. An additional objective was to determine effects of vacuum packaging after dry aging on dry-aged flavor stability of steaks

Supplementary Material for: What Went Wrong with VEGF-A in Peripheral Arterial Disease? A Systematic Review and Biological Insights on Future Therapeutics

Background: Of the 200 million patients worldwide affected by peripheral arterial disease (PAD), 4% will inevitably require major limb amputation. Previous systematic reviews presented a conflicting body of evidence in terms of vascular endothelial growth factor (VEGF) family member effects upon PAD natural progression. Despite that, modulation of intrinsic angiogenesis mechanisms targeting the VEGF family members still confers an attractive therapeutic target. The aim of the present study was to evaluate current evidence of VEGF modulation in the context of PAD. Methods: This is a systematic literature review conducted according to the PRISMA guidelines and registered under PROSPERO database [CRD42021285988]. Independent literature search was performed up to April 1, 2022, on six databases. A total of 22 eligible studies were identified [N: 3, interventional patient studies; N: 19, animal studies]. Animal studies were appraised by the SYRCLE risk of bias tool, while human participant studies were assessed by the Newcastle Ottawa scale. Overall, quality of evidence was deemed fair for both animal and human studies. Main study outcomes were percentage change of injured vessel lumen stenosis and neointimal area formation upon VEGF modulation (inhibition or activation) in comparison with control group. Findings: Nineteen animal models and three human participant studies were included in the systematic review and assessed separately. Positive modulation of VEGF-A in animal models resulted in a median decrease of 65.58% [95% CI 45.2; 71.87] in lumen stenosis [14 studies]. Furthermore, positive modulation of VEGF-A was found to reduce neointimal area proliferation by a median decrease of 63.41% [95% CI 41.6; 79.59] [14 studies]. Median end of study duration was 28 days [range: 14–84 days]. Data were insufficient to assess these outcomes with respect to VEGF-B or VEGF-C modulation. The limited number of available human studies presented inadequate outcome assessment despite their overall fair NOS grading. Interpretation: VEGF-A-positive modulation decreases lumen stenosis and neointimal hyperplasia in PAD simulation animal models. Previously identified variability among outcomes was found to strongly stem from the variability of experimental designs. Clinical applicability and safety profile of VEGF-A in the context of PAD remain to be defined by a robust and uniformly designed body of further animal model-based experiments

Estudo comparado do desenvolvimento pós-embrionário de Cochliomyia macellaria (Fabricius) (Diptera, Calliphoridae) em duas dietas à base de carne, em laboratório Comparative studyy of post-embryonic development of Cochliomyia macellaria(Fabricius) (Diptera, Calliphoridae) under two meat diets, in laboratory

<abstract language="eng">The influence of a diet based on putrid horse meat over the post-embryonic development of Cochliomyia macellaria (Fabricius, 1775) under controlled conditions (UR 65 10% and 14 hours of photophase) was compared with the results obtained using a meat broth diet to which other sources of animal and vegetable protein were added. The flies were maintained at 30ºC, from egg until mature larvae spontaneously abandoned the diet. They were then transfered to a climatized chamber at 27ºC. The larvae and pupae viability and the weight of the mature larvae were significantly inferior, when a diet based on meat broth was used, even though the larvae period was significantly increased with this diet. This type of diet did not charge the time of development of the pupae. The inoculation of the egg mass directly over the diet was recommend, instead of the technique in which the egg masses are transfered to humid filter paper, followed by the handling of the recently ecloded larvae

E-rosette positive acute lymphoblastic leukaemia in adolescents and adults

E-rosetting of leukaemic blast cells is one of the markers of T-cell acute lymphoblastic leukaemia (ALL). In children, E+ ALL has a bad prognosis. In adults, data are scarce. This report provides information on 25 E+ ALL adult patients who have a minimum follow-up time of 36 months. Twenty-two of 25 patients (88%) achieved complete remission (CR) (median duration 16 months), and six of them were alive, relapse-free, and off therapy after 36-81 months, with a 26% projected 6-year relapse-free survival. In 97 patients with E-SmIg- ALL, who were treated at the same Institutions, over the same period of time, and by the same modalities, the outcome of therapy was almost identical: CR 80%, median duration of first CR 15 months, projected 6-year relapse-free survival 15%. The white blood cell (WBC) count at presentation influenced significantly and to the same degree of first CR length in both E+ and E- cases. In this adult series, WBC count was not as high as in children. Moreover, a high Hb concentration, a very high WBC count, lymphadenomegaly, and mediastinal involvement, were found more frequently in adolescents and young adults than in adults. Based on these data, it is suggested that in adults E-rosetting as such is not a marker of a poorer prognosis, that some of the typical features of children E+ ALL weaken with age, and that in adults the disease can have a less aggressive character